Comparative Pharmacology
Head-to-head clinical analysis: ALUNBRIG versus ROZLYTREK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUNBRIG versus ROZLYTREK.
ALUNBRIG vs ROZLYTREK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alunbrig (brigatinib) is a tyrosine kinase inhibitor that targets ALK and ROS1. It inhibits autophosphorylation of ALK and ALK-mediated activation of downstream signaling proteins STAT3, AKT, ERK1/2, and PLCγ in ALK-dependent tumor cells.
Entrectinib is a potent inhibitor of tropomyosin receptor tyrosine kinases (TRK) A, B, and C, and also inhibits ROS1 and ALK. It blocks downstream signaling pathways including MAPK, PI3K/AKT, and PLCγ, leading to apoptosis and reduced tumor growth in cancers with NTRK or ROS1 fusions.
90 mg orally once daily for first 7 days, then increase to 180 mg orally once daily
200 mg orally once daily with or without food.
None Documented
None Documented
Terminal half-life approximately 25 hours. Supports once-daily dosing; steady state achieved in ~5 days.
Terminal half-life approximately 24 hours; supports once-daily dosing, steady-state reached in ~5 days.
Primarily hepatic metabolism (CYP3A4); 65% fecal (unchanged and metabolites), 25% renal (1% unchanged). Biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism via CYP3A4; 63% of dose recovered in feces (mostly as metabolites), 18% in urine (9% unchanged).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor